Relmapirazin , CAS No.1313706-17-0

CAS: 1313706-17-0 Cat. No.: R1449827 分子式: C₁₂H₁₆N₆O₈ 分子量: 372.29

Storage

Store at -20°C

Shipped In

Ice chest + Ice pads

概要

Relmapirazin (MB-102) is a fluorescent tracer agent for real-time measurement of glomerular filtration rate.

Specifications

保管条件

Store at -20°C

入荷

Ice chest + Ice pads

この製品は冷冷この冷このこの製品の運送が必要です。地上およびその他の経済サービスは利用できません。

名前と識別子

分子量

372.29

Application Protocols

No tested applications or validated protocols are provided in the Product Data for Relmapirazin. The following general guidance may assist in establishing internal SOPs for small-molecule handling in biochemical/cellular assays.

General protocol outline (non-item-specific):

1. Stock preparation

• Accurately weigh compound in a low-humidity environment.
• Dissolve in DMSO to prepare a concentrated stock (e.g., 10–50 mM). Vortex and, if needed, sonicate briefly. Record exact concentration.

2. Working solution

• Dilute stock into assay buffer or culture medium to achieve the desired final concentration, maintaining constant final DMSO (e.g., ≤0.1–0.5% v/v).
• Inspect for precipitation; if present, lower concentration or adjust vehicle.

3. Control setup

• Include vehicle controls, positive controls (if available), and cytotoxicity assessments.

4. Stability checks

• Evaluate bench-top and incubation stability by LC–MS or HPLC over the assay window; avoid repeated freeze–thaw of stocks.

Item-specific dilutions, positive controls, or detection methods: Not specified for this item; refer to CoA/Spec Sheet.

Biological Roles

No target, pathway, or mechanism of action is provided in the Product Data for Relmapirazin. The following notes are general considerations for small-molecule research tools and should not be interpreted as item-specific claims.

General considerations:

• Potential roles: Small molecules in this category are typically used to modulate or probe protein targets (enzymes, receptors, transporters) or pathways in biochemical and cellular assays. Verify the specific target, potency, and selectivity for Relmapirazin from primary literature or the CoA if available.
• Off-target assessment: When target is unknown or incompletely characterized, include orthogonal assays and appropriate counterscreens to identify nonspecific effects (e.g., aggregation, redox cycling, assay interference like fluorescence quenching).
• ADME-relevant properties: Solubility, permeability, and stability (plasma, microsomal, chemical) determine utility in biological systems. These data are not provided and should be empirically determined if needed.

Experimental guidance:

• Prepare well-characterized DMSO stocks and verify concentration by UV or quantitative NMR where possible.
• Use multiple concentrations spanning at least an order of magnitude around expected activity; include vehicle controls and cytotoxicity controls.

Research use limitation:

• For research use only. Not for human or veterinary use, diagnostic procedures, or clinical applications.

Buffer Applications

This listing is a small-molecule research compound, not a buffering reagent. Therefore, classic buffer-system guidance (pKa, buffering range, recipes) is not typically applicable.

Practical notes (general):

• When dosing into aqueous buffers, pre-dissolve the compound in a miscible organic solvent (commonly DMSO), then dilute into buffer while mixing to avoid precipitation.
• Maintain consistent final organic cosolvent across conditions (e.g., ≤0.1–1% v/v DMSO) to avoid confounding biological results.
• If pH-dependent solubility is suspected, evaluate solubility across pH 2–9 using appropriate buffers (citrate, phosphate, Tris) and confirm recovery by HPLC.

Item-specific buffering parameters (pKa, buffer capacity): Not specified for this item; refer to CoA/Spec Sheet.

Green Alternatives

Green chemistry considerations primarily pertain to handling solvents and formulation vehicles for stock solutions, as the active compound itself is fixed.

Greener solvent choices for solution preparation (general guidance):

• Replace or minimize high-toxicity aprotic solvents (e.g., DMF, NMP). Prefer DMSO (with care in biological systems) or bio-based/safer alcohols where feasible.
• For assay dilution, use buffered aqueous media with minimal cosolvent (<0.5–1% v/v organic) when solubility allows.

Comparison (general, not item-specific):

• DMSO vs DMF: DMSO has lower acute toxicity and better biodegradability; DMF is a reproductive toxin—avoid unless necessary.
• Ethanol vs acetonitrile: Ethanol is greener and widely biocompatible at low percentages; acetonitrile is more hazardous and less sustainable.
• 2-MeTHF/CPME (for synthesis contexts) vs THF/diethyl ether: Greener ethers reduce peroxide risk and improve sustainability; this is less relevant if the compound is only used as a bioactive tool.

Operational improvements:

• Scale down assays to minimize solvent and compound use.
• Implement closed-vial handling and cold-chain efficiency to reduce dry ice/ice pack waste.
• Use glassware/vials that are reusable and compatible with your compound to limit single-use plastics.

Note: No item-specific stabilizers or solvent requirements are provided; confirm compatibility with your biological system and analytical methods.

Pharmaceutical Uses

No pharmacopeial status, excipient role, or formulation details are provided for this item. Aladdin Scientific supplies this compound strictly for research use only.

Context (general, not item-specific):

• Small molecules like this may be utilized as reference standards, method-development controls, or tool compounds in preclinical research settings.
• If used in formulation research (in vitro only), typical vehicles include DMSO, ethanol, PEG 300/400, or aqueous buffers with surfactants; compatibility and stability must be verified experimentally.
• No claims are made regarding clinical suitability, GMP status, or pharmacopoeial compliance.

Compliance note:

• Not for human or veterinary use. Not intended for diagnostic or therapeutic applications. For any regulated use, obtain appropriate grade, documentation, and regulatory clearance.

Physical Properties

Item-specific physical constants are not included in the provided data. Do not treat any value below as a specification.

Item-specific specs:

• Appearance: Not specified for this item; refer to CoA/Spec Sheet.
• Grade/Purity: Not specified for this item; refer to CoA/Spec Sheet.
• Molecular weight: Not specified for this item; refer to CoA/Spec Sheet.

General/literature guidance (not item-specific):

• Melting point (if solid) and boiling point (if liquid) for Relmapirazin have not been provided. Consult CoA or determine experimentally (DSC/melting point apparatus or TGA/DSC for thermal behavior).
• Solubility: For small-molecule research tools, initial dissolution is commonly assessed in DMSO (analytical grade); aqueous solubility can then be estimated by dilution into buffered media with surfactant or cosolvent if needed. Empirically determine by serial dilution and visual inspection, backed by HPLC area-percent recovery.
• Partitioning: LogP/logD and pKa (if ionizable) control solubility and permeability, but are not provided here. Consider measuring by potentiometric titration or LC–MS retention time proxies.
• Density, refractive index: Not applicable unless a neat liquid; values are not provided.

Practical tips:

• If hygroscopicity or polymorphism is a concern, verify by Karl Fischer and PXRD respectively (general advice).
• Establish a validated identity/assay method (e.g., 1H NMR in DMSO‑d6 or CDCl3; HPLC/UPLC with diode array/MS detection).

Quality and Grades

The provided Product Data do not specify a formal quality grade or purity for Relmapirazin.

Item-specific details:

• Grade/Purity: Not specified for this item; refer to CoA/Spec Sheet.

General guidance on grades (for context only):

• Research grade typically ensures identity confirmation (e.g., NMR/HRMS) and assay by HPLC/UPLC. Impurity limits, water content, and residual solvents vary by supplier and batch.
• If “HPLC grade” or “BioUltra” types are indicated (not specified here), they typically relate to solvent/consumable purity, not to small-molecule APIs—verify the meaning for the specific product line.
• UV cutoffs, metal content, and stabilizers are not listed for this item; if your application is spectroscopic or catalytic, request these data on the CoA.

Recommendations:

• Request batch CoA for: assay (% area by HPLC), identity (1H NMR/LC–MS), residual solvent profile (GC), and water content (KF), especially for quantitative biology or medicinal chemistry studies.
• If your workflow requires salt form control or polymorph specificity, confirm via XRPD, DSC, and 13C CPMAS as appropriate.

Reaction and Applications

This product is listed under Life Science and is intended as a research-use small molecule rather than a synthetic reagent. No manufacturer reaction/application notes are provided.

Likely usage modes (general, non-item-specific):

• As a tool compound in biochemical, cellular, or target-engagement assays (e.g., binding, reporter gene, or phenotypic screens). Specific target class or mechanism is not provided—verify via primary literature or CoA notes.
• As a reference standard for LC–MS method development and quantitative bioanalysis (prepare certified stocks; verify response factors with internal standard).
• In medicinal chemistry SAR: may serve as a comparator/control molecule in panels. Ensure identical solvent and dosing protocols across series to avoid vehicle effects.

Analytical tips:

• Establish a stability-indicating HPLC/UPLC method. Track degradation under assay conditions (pH, temperature, light) using LC–MS.
• Perform freeze–thaw stability and bench-top stability studies on working solutions.

Not a general synthetic reagent: No named reactions or catalytic roles are associated with this listing in the Product Data. If synthetic transformations are intended, first obtain full structural and stability details from the CoA and literature.

Reaction Conditions

No synthetic or reaction-use guidance is provided for this product and, given its listing context (Life Science research compound), it is not positioned as a reagent or catalyst.

Therefore, there are no item-specific reaction conditions, catalysts, or yields to report. If you have obtained the chemical structure and intend to perform derivatization or analog synthesis, establish conditions empirically:

• Solvent selection: Match to substrate polarity and stability; start with dry aprotic solvents (DCM, MeCN, DMF) or alcohols as appropriate.
• Temperature: Screen 0–80°C initially; monitor by TLC or LC–MS.
• Catalysts/bases/acids: Choose based on functional groups present (unknown here). Avoid strong conditions until stability is confirmed.
• Workup: Optimize quench and extraction to prevent product loss or decomposition.

Labeling note: Any conditions reported in literature for Relmapirazin analogs should be clearly cited and not assumed to apply to this exact item without verification.

Safety and Handling

Safety data specific to this item have not been provided in the product data. Always consult the product SDS for authoritative information.

Item-specific hazard fields:

• GHS classification: Not specified for this item; refer to SDS.
• Signal word: Not specified for this item; refer to SDS.
• Hazard (H) statements: Not specified for this item; refer to SDS.
• Pictograms: Not specified for this item; refer to SDS.

General laboratory precautions for small-molecule research compounds:

• PPE: Use lab coat, safety glasses, and appropriate chemically resistant gloves (e.g., nitrile). Handle powders in a fume hood to avoid inhalation and dust generation.
• Avoid contact with skin, eyes, and clothing. Prevent ingestion and inhalation. Do not pipette by mouth.
• Storage incompatibilities: Until specific functional groups are known, segregate from strong oxidizers and strong acids/bases. Keep container tightly closed, desiccated, and protected from moisture. Follow the item-specific storage condition below.
• Spill/Exposure: For small spills, absorb with inert material; avoid dust. In case of eye/skin contact, rinse with water for at least 15 minutes and seek medical attention per SDS.
• Waste: Dispose of according to institutional and local regulations for organic laboratory chemicals; do not discharge to drains.

Item-specific storage guidance from Product Data:

• Storage: Store at −20°C.
• Shipping: Shipped in an ice chest with ice pads to maintain cold chain.

Peroxide formation, pyrophoricity, or volatility are not indicated; verify hazards via SDS before scale-up.

Solvent Selection

Because no structural/ionization information is provided for Relmapirazin, solvent selection should be established empirically.

Practical strategy for small-molecule stocks (general guidance):

• Primary solvent: Start with anhydrous DMSO to prepare a concentrated stock (e.g., 10–50 mM), then dilute into assay buffer or culture medium with vigorous mixing to avoid precipitation.
• Alternatives if DMSO is unsuitable: DMF, ethanol, or 1:1 ethanol:propylene glycol can be screened; for basic compounds, 0.1–1% HCl in aqueous ethanol may improve solubility; for acidic compounds, 0.1–1% NaOH in water/MeOH may help. Validate compatibility with biological systems before use.
• Aqueous work: Use buffer with surfactant (e.g., 0.01–0.1% Tween 80 or Pluronic F-68) to enhance wetting and minimize aggregation (if biologically compatible).

Selection considerations:

• Polarity/logD unknown: Confirm by small-scale solubility tests and LC–MS recovery.
• Photolability unknown: When in doubt, protect solutions from light (amber vials, foil).
• Adsorption: If compound is lipophilic, adsorption to plastics can be significant; use glass vials or low-bind plastics.

Documentation:

• Record solvent lot, concentration, pH, and any cosolvents used. Filter through 0.22 µm only after confirming no retention losses.

Storage and Reconstitution

Item-specific storage and shipping conditions (from Product Data):

• Storage: Store at −20°C.
• Shipping: Shipped in ice chest with ice pads to preserve cold chain.

General reconstitution guidance for small molecules (not item-specific):

• Upon receipt, allow the sealed container to equilibrate to room temperature before opening to prevent moisture condensation.
• If supplied as a solid: Prepare a DMSO stock solution (e.g., 10–50 mM) in a dry environment. Aliquot into amber, tightly sealed vials to minimize headspace and freeze–thaw cycles.
• If supplied as a solution: Verify solvent, concentration, and stabilizers on the label/CoA. Store as directed; do not dilute into water unless compatibility is known.
• Protect from moisture and, if chromophores are suspected, from light (amber glass, foil wrap) as a precaution.

Stability notes:

• Long-term stability, hygroscopicity, and light sensitivity are not specified for this item; consult the CoA/SDS and perform a small-scale stability study if critical to your application.
• Avoid repeated freeze–thaw. Prepare single-use aliquots and keep a usage log (date opened, storage history).

Research use only: Not for human or veterinary use.

Structure and Identity

Brief overview: This listing is for Relmapirazin (SKU: R1449827), offered for research use only.

• Product name: Relmapirazin
• CAS: 1313706-17-0
• Molecular formula: Not specified for this item; refer to CoA/Spec Sheet.
• Molecular weight: Not specified for this item; refer to CoA/Spec Sheet.
• SMILES: Not specified for this item; refer to CoA/Spec Sheet.
• InChIKey: Not specified for this item; refer to CoA/Spec Sheet.
• Structural features: Not specified for this item; refer to CoA/Spec Sheet.

Descriptive structure (general): No structure has been provided in the product data. If you require definitive identity attributes (2D/3D structure, stereochemistry, salt form, or polymorph information), please consult the Certificate of Analysis (CoA) or request the technical specification sheet from Aladdin Scientific.

Notes for users:

• Please confirm exact identity (free base vs. salt, hydrate/solvate state, and stereochemical configuration if any) prior to quantitative work.
• For cheminformatics registration or analytical method development (HPLC/LC–MS, NMR), authoritative identifiers (SMILES/InChIKey) must be sourced from the CoA or a validated primary reference.

Synthetic Utility

Relmapirazin is offered as a research-use small molecule, not as a synthetic building block or reagent in this catalog entry. No functional-group information or reactivity profile is provided.

Accordingly:

• Named reactions, protecting-group strategies, and coupling methodologies cannot be recommended without structural disclosure.
• If you intend to employ this compound in synthesis (e.g., as a coupling partner, fragment, or scaffold), please request the full structural information and assess compatibility with planned transformations (sensitivity to acid/base, redox, heat, light).

General best practices (non-item-specific):

• Confirm identity and purity by orthogonal methods (NMR, HRMS, HPLC) before use as a substrate or standard.
• Conduct a small-scale compatibility screen with envisaged reagents/conditions to detect instability (hydrolysis, oxidation, rearrangement).
• Track mass balance and impurity profiles by LC–MS to ensure no carryover of reactive impurities into subsequent steps.

Target Specificity

This section applies to biologics (e.g., antibodies, proteins). Relmapirazin is listed as a small-molecule research compound, and no biologic target specificity (antigen, clone, isotype, species reactivity) is provided.

• Item-specific target data: Not applicable; not an antibody or protein reagent.
• For small-molecule targets/mechanisms (e.g., enzyme, receptor), no information is provided in the Product Data. Consult CoA or primary literature if available.